Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer ...
Find similar stocks with Morningstar Investor.
Provided by Dow Jones Nov 13, 2026, 6:56:00 PM ...
Will PRWCX outperform in the future? Get our overall rating based on a fundamental assessment of the pillars below. The last time new investors could buy shares of T. Rowe Price Capital Appreciation, ...
There is no Morningstar’s Analysis data available.
A topnotch high-yield muni offering. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market cycle on a ...
A disciplined approach built to endure. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market cycle ...
More team changes coming in 2026. Our research team assigns Neutral ratings to strategies they’re not confident will outperform their Morningstar Category average over a market cycle on a ...
Consistency backed by scale and skill. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market cycle on ...
Our research team assigns Silver ratings to strategies that they have a high conviction will outperform their Morningstar Category average over a market cycle on a risk-adjusted basis. American Funds' ...
A strong option despite a recent cold streak. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results